Fulgent Genetics (NASDAQ:FLGT) Reaches New 52-Week Low at $20.32

Fulgent Genetics, Inc. (NASDAQ:FLGT) shares reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $20.32 and last traded at $20.37, with a volume of 83945 shares traded. The stock had previously closed at $20.72.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler lowered their price target on Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating for the company in a research report on Wednesday, March 6th.

Fulgent Genetics Stock Performance

The stock has a 50-day simple moving average of $22.76 and a two-hundred day simple moving average of $25.39. The firm has a market cap of $608.76 million, a PE ratio of -3.57 and a beta of 1.43.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Wednesday, February 28th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.61. Fulgent Genetics had a negative return on equity of 3.04% and a negative net margin of 58.03%. The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $67.14 million. As a group, sell-side analysts anticipate that Fulgent Genetics, Inc. will post -2.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Fulgent Genetics

A number of hedge funds have recently bought and sold shares of FLGT. Covington Capital Management increased its position in shares of Fulgent Genetics by 133.3% during the 3rd quarter. Covington Capital Management now owns 700 shares of the company’s stock valued at $27,000 after purchasing an additional 400 shares during the last quarter. Geneos Wealth Management Inc. increased its position in shares of Fulgent Genetics by 416.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 491 shares of the company’s stock valued at $30,000 after purchasing an additional 396 shares during the last quarter. Asset Management One Co. Ltd. purchased a new stake in shares of Fulgent Genetics during the 3rd quarter valued at about $34,000. Covestor Ltd increased its position in shares of Fulgent Genetics by 48.0% during the 3rd quarter. Covestor Ltd now owns 1,508 shares of the company’s stock valued at $40,000 after purchasing an additional 489 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in shares of Fulgent Genetics during the 4th quarter valued at about $46,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.